Top Injectable Manufacturer in Botswana – Reliable Pharmaceutical Solutions
- Maulik Sudani
- 2 days ago
- 9 min read
Last Updated: September 4, 2026
TL;DR: Botswana answers the question we always ask first — does the country keep a list of regulators it will rely on, and is India on it — with a reliance pathway that visibly exists and a list we could not read. The Botswana Medicines Regulatory Authority, BoMRA, created under the Medicines and Related Substances Act of 2013, opened a reliance-based expedited registration window for veterinary products in May 2026 and says it is building a BoMRA Reliance Framework aligned to the continental framework of AUDA-NEPAD; its guideline and fee libraries sit behind a document plugin that returned no text, so whether India's CDSCO is named, excluded or covered by a general clause is unknown in both directions. What is published is the procedure — screening with a fee, then application fees, samples and a signed form, scientific evaluation, a query letter and a Registration Committee decision — and a five-year marketing authorisation. Botswana is a founding member of the ZaZiBoNa work-sharing initiative. The commercial gate is the Central Medical Stores of the Ministry of Health, buying through the national e-tender portal, in a country that declared a public health emergency over medicine shortages in August 2025 and whose Health Minister travelled to Ahmedabad in 2022 to negotiate with Indian suppliers.
Key Takeaways
A reliance route exists; its reference list is unread. BoMRA's expedited reliance-based registration was opened for veterinary medicines from 1 May to 31 July 2026 and the authority states that a BoMRA Reliance Framework aligned to the AUDA-NEPAD Continental Reliance Framework is in development. We could not read the guideline or fee documents, so we do not say whether the human-medicines route is open or whether India is on any list.
The published procedure is sequential and fee-gated. A full dossier goes in with a screening fee for a completeness check; after screening the applicant is told to pay the application fee, submit samples and a signed form; scientific evaluation follows, then a query letter with a deadline and a decision by the Registration Committee. The marketing authorisation runs for five years and must be renewed. Timelines are set out in a service-standards document we could not retrieve.
The regional layer is real. Botswana co-founded ZaZiBoNa with Zambia, Zimbabwe and Namibia in 2013, the SADC work-sharing initiative for joint dossier assessment. Neither Botswana nor India is a PIC/S participating authority, and BoMRA is not on the WHO's August 2026 list of maturity-level-3 authorities, having completed an assisted self-benchmarking exercise in August 2025.
The buyer is the State, and the State has been short of medicines. Out-of-pocket spending is only 4.3% of health expenditure, so Central Medical Stores tenders on the national e-tender portal are the market. Botswana declared a public health emergency over medicine shortages in August 2025, with essential-medicine availability reported at 17% that month and 36% by October, and the Health Minister led a delegation to Ahmedabad and New Delhi in late 2022 to negotiate with Indian suppliers.
Introduction: Why Botswana Demands a Premium Injectable Manufacturer in Botswana
Every market in this series opens with the same question: does the country publish a list of regulatory authorities whose decisions it will lean on, and is India's CDSCO among them? Botswana gives an answer we have met before in a new form. The regulator is the Botswana Medicines Regulatory Authority, BoMRA, a body corporate under the Medicines and Related Substances Act of 2013 that regulates human and veterinary medicines, medical devices and cosmetics. BoMRA plainly operates a reliance concept: in 2026 it opened a reliance-based expedited registration window for veterinary medicinal products, from 1 May to 31 July, and it states that a BoMRA Reliance Framework aligned to the AUDA-NEPAD Continental Reliance Framework is being developed. A reliance framework implies a list of authorities whose work is relied on. We went looking for that list and could not read it: the authority's guidelines and fee schedules are published through a document-download plugin that returned no titles and no text to us, and no page of the site we could read names a reference authority.
So we do not say that India is on a Botswana list, and we do not say it is absent; the honest position is unknown in both directions. There is one risk worth stating in advance. Continental reliance frameworks often reach for the WHO's Global Benchmarking Tool and admit authorities at maturity level 3 or above. On the WHO's August 2026 list, India's CDSCO is benchmarked at level 3 for vaccines only, not for medicines, so a clause of that shape would not admit a small-molecule sterile injectable from India. That is a hypothesis about a document we have not read, not a finding, and we flag it so that a buyer can check it against the framework when it is published. What is not in doubt is the shape of the market a premium injectable manufacturer in Botswana must serve: a public system that finances almost all medicine and that spent 2025 in a declared shortage emergency.
What Sets a World-Class Injectable Manufacturer in Botswana Apart
The published procedure is more sequential than most in the region, and the sequence matters for planning. A full product dossier is submitted together with a screening fee; screening is a completeness check, not an assessment. Once the dossier passes screening the applicant is advised to pay the application fees, to submit product samples and to lodge a signed application form. Scientific evaluation follows, then a query letter with a deadline for the response, and finally a decision by the Registration Committee. BoMRA refers applicants to its service standards for timelines; we could not retrieve that document, so we quote no number of days. The authority's own answer to how long registration takes is that it can take several months. A marketing authorisation is valid for five years, after which a renewal application is required, and variations are handled as a separate procedure. There is also an exemption route for essential unregistered products urgently needed for public health, which became relevant during the 2025 shortage.
Several things a supplier would normally settle from the guidelines we cannot settle here. Whether the common technical document is mandatory at first submission, whether a local applicant, agent or pharmacovigilance contact must be appointed, how many samples are required and in what language the file is examined are all questions the guideline library would answer and that we were unable to read. The screening fee is reported at 500 pula and an annual retention fee falls due by 31 March; we have not seen the instrument that sets registration, renewal or inspection fees and quote none of those. What is clear from BoMRA's public pages is that the authority inspects for good manufacturing, distribution and pharmacy practice along the supply chain and that it will inspect a manufacturing or storage establishment at a prescribed fee, so a foreign site should expect to be assessed rather than simply certified. BoMRA also registers distributors separately, which is the route a Botswana importer or wholesaler must follow before it can carry a product.
Quality Systems Behind Every Injectable Supplied to Botswana
For a sterile injectable the evidence an assessor and an inspector expect is the same everywhere: aseptic process simulation records for the ISO Class 5 filling line, environmental monitoring trends, container-closure integrity, sterility and bacterial endotoxin testing by LAL, particulate matter, validated HPLC and GC assay and impurity methods, and ICH Q1A and Q1B stability data appropriate to a hot, dry climate with wide temperature swings rather than data extrapolated from a temperate one. Because BoMRA reserves the right to inspect the establishment, the batch records, deviation logs and change controls behind those results should be ready to be walked through, not just summarised.
The regional layer sets the wider expectation. Botswana co-founded ZaZiBoNa in October 2013 with Zambia, Zimbabwe and Namibia, the SADC work-sharing initiative under which assessors from participating authorities review dossiers jointly and inspect sites together; a file prepared to ZaZiBoNa's common standard therefore travels. Neither Botswana nor India appears on the PIC/S list of participating authorities, and BoMRA is not on the WHO's August 2026 list of authorities at maturity level 3 or 4, having completed a five-day assisted self-benchmarking exercise with the WHO in August 2025. Botswana's ratification of the African Medicines Agency treaty is reported for February 2025, but the agency's own page does not name the country in readable text, so we record the report as unconfirmed.
Looking for a sterile injectable manufacturing partner? Talk to Farbe Firma about your market entry.
Why Farbe Firma is the Trusted Injectable Manufacturer in Botswana for Global Buyers
Farbe Firma Pvt Ltd is a WHO-GMP certified sterile injectable manufacturer and CDMO based in Gujarat, India, filling under ISO Class 5 conditions and exporting to more than thirty countries. We build dossiers in CTD and ACTD format, which is the structure ZaZiBoNa assessments and every SADC authority we have dealt with work from, and we can give the written commitment to a full CTD file that BoMRA material refers to without hesitation because the file already exists in that form. We supply the WHO-format certificate of a pharmaceutical product, the manufacturing licence and the GMP certificate as a matter of course, and we treat a request for a site inspection as a normal part of doing business rather than an obstacle. Where the reliance framework, when published, names authorities that do not include India, our answer is a complete stand-alone file assessed on its merits, which is the route we take in most of the markets in this series.
The bilateral relationship is substantial and pharmaceuticals are already part of it. The Indian High Commission's brief of January 2026 records bilateral trade of USD 506.34 million in 2024–25, with Indian exports of USD 173.44 million and imports of USD 332.90 million, the imbalance reflecting Botswana's diamond exports, and it lists pharmaceuticals explicitly among India's exports to Botswana and names pharmaceuticals and medical devices as an identified opportunity for expansion. The single most useful commercial fact for a Gujarat manufacturer is that Botswana's Minister of Health led a five-member delegation to Ahmedabad and New Delhi from 28 November to 1 December 2022 for negotiations with Indian medical suppliers. We do not quote a UN Comtrade figure for pharmaceutical trade because the database returned nothing usable to us for this pair, and no health memorandum or regulator-to-regulator agreement between CDSCO and BoMRA is mentioned in the brief.
Where the money is: Botswana has 2.56 million people, gross national income per capita of USD 7,390 in 2025, current health expenditure of about USD 490 per person and 6.3% of GDP in 2023, and life expectancy of 69.3 years. Out-of-pocket payments were 4.3% of health expenditure in 2023, among the lowest shares anywhere, so the State pays for medicine and the Central Medical Stores of the Ministry of Health, procuring, storing and distributing for public facilities and tendering on the national e-tender portal, is the commercial gate; private wholesalers, pharmacies and the BPOMAS and BOMAID medical-aid schemes serve the rest. HIV prevalence among adults was 15.7% and tuberculosis incidence 143 per 100,000 in 2024, both falling, both sustaining demand for sterile anti-infectives. In August 2025 the government declared a public health emergency over medicine shortages, attributed to weak diamond revenue and the loss of donor funding, with essential-medicine availability reported at 17% that month and 36% by early October and about USD 75 million owed to private suppliers; a supplier entering now should price and contract with that payment history in view, and should expect the shortage-driven exemption route and emergency procurement to coexist with the normal one.
Explore Farbe Firma: Products | Global Reach | About Us
Frequently Asked Questions (FAQ)
Is India on Botswana's list of recognised regulatory authorities?
Unknown in both directions. BoMRA operates a reliance concept — a reliance-based expedited window was opened for veterinary medicines in May 2026 and a BoMRA Reliance Framework aligned to the AUDA-NEPAD Continental Reliance Framework is described as under development — but the guideline and fee documents that would carry a reference list are published through a download plugin that returned no text to us, and no readable page names a reference authority. We therefore neither claim nor deny that CDSCO is recognised. Note that on the WHO's August 2026 list CDSCO is benchmarked at maturity level 3 for vaccines only, so a generic level-3 clause would not cover a small-molecule injectable.
What does the BoMRA registration procedure look like?
A full dossier is submitted with a screening fee for a completeness check; after screening the applicant pays the application fees and submits samples and a signed application form; scientific evaluation follows, then a query letter with a response deadline, and the Registration Committee decides. The marketing authorisation is valid for five years and must then be renewed. Timelines are set in a service-standards document we could not retrieve, and BoMRA's own guidance says registration can take several months.
Which fees and dossier rules apply?
The screening fee is reported at 500 pula and an annual retention fee falls due by 31 March. We have not seen the instrument that sets registration, renewal or GMP-inspection fees, so we quote none, and we could not read the guideline that would settle CTD format, local applicant, sample and language requirements. BoMRA states that it inspects establishments along the supply chain at a prescribed fee and registers distributors separately.
Who buys injectables in Botswana?
Overwhelmingly the State. Out-of-pocket spending was 4.3% of health expenditure in 2023, so the Central Medical Stores of the Ministry of Health, which procures, stores and distributes for public facilities and tenders on the national e-tender portal, is the commercial gate, with private wholesalers, pharmacies and medical-aid schemes such as BPOMAS and BOMAID serving the private sector. A public health emergency over medicine shortages was declared in August 2025 and about USD 75 million was reported owed to private suppliers, so payment terms deserve attention.
Does Farbe Firma have experience with SADC and ZaZiBoNa-style markets?
Yes. Farbe Firma is a WHO-GMP certified sterile injectable manufacturer and CDMO in Gujarat, India, filling under ISO Class 5 conditions and exporting to more than 30 countries, several of them in the SADC region. We prepare dossiers in CTD and ACTD format, supply the WHO-format CPP, manufacturing licence and GMP certificate, and are ready for a site inspection. Write to director@farbefirma.org with the product list and we will map the file to BoMRA's sequence.
Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert)
Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA
Request a Quote | View Products | FAQ | Blog
Comments